Gaetano Scuderi, MD’s Post

View profile for Gaetano Scuderi, MD

Orthopaedic Surgeon 4th Degree VB jiujitsu black belt

View profile for Joey Bose

President & CEO of Cytonics | Johns Hopkins School of Medicine | Moving From Insurmountable Challenge To Almost Certain Failure With Unbridled Enthusiasm

🎉 Major Phase 1 Study Milestone Achieved! 🚨 First Nine Patients Complete Study with No Adverse Events We’re thrilled to share a major milestone in the development of CYT-108, Cytonics Corporation's groundbreaking biologic therapy for osteoarthritis: ✅ The first nine patients in our Phase 1 clinical trial have completed the study, including dosing on Day 0 and Day 90, with follow-up through Day 180. 🛡️ Most importantly, no drug-related adverse events were reported, affirming CYT-108’s safety profile and paving the way for the next stage of development. 🔬 Why This Matters CYT-108 is a recombinant variant of alpha-2-macroglobulin (A2M), a naturally occurring protein that protects cartilage by neutralizing enzymes that degrade it. Engineered to target and inhibit the proteases responsible for cartilage damage, CYT-108 is positioned as a potential disease-modifying therapy—a first for osteoarthritis. 🚀 Next Steps: Advancing to Phase 2 This milestone brings us closer to initiating Phase 2 clinical trials, where we will evaluate CYT-108’s efficacy in a larger group of patients and gather data on pain reduction and joint function improvement. #Cytonics #arthritis #clinicaltrials #regenerativemedicine #drugdevelopment

  • No alternative text description for this image
Kathy Giori

Tricyrcle CEO | MicroBlocks Partnerships | Strategic Advisor

1mo

Exciting milestone indeed! Hurry up through the next trial phases before I need this therapy! 😂 Major kudos Gaetano Scuderi, MD 🤩

Very informative

Michael Maglio, MPS, CTP

Vice President of Industrial Sales | Political Communication Strategic Public Relations

1mo

Love this

JEIMYLO DE CASTRO MD,FPARM,RMSK, DABRM, CIPS

Medical Director/CEO at SMARTMD Philippines

1mo

Great breakthrough!

See more comments

To view or add a comment, sign in

Explore topics